{"id":"NCT01151098","sponsor":"Purdue Pharma LP","briefTitle":"Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study","officialTitle":"An Open-Label, Multi-Center, Titration Study to Establish the Long-term Safety and Tolerability of Buprenorphine Transdermal Delivery System (BTDS) 5 mg, 10 mg, and 20 mg in Patients With Chronic Non-Malignant Pain Syndromes Responsive to Opioid Combination Therapy - a 28-Week Extension Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-04","primaryCompletion":"2002-02","completion":"2002-02","firstPosted":"2010-06-25","resultsPosted":"2010-09-23","lastUpdate":"2012-09-10"},"enrollment":189,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Nonmalignant Pain"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":["Butransâ„¢"]}],"arms":[{"label":"BTDS 5, 10 or 20","type":"EXPERIMENTAL"}],"summary":"The objective of this study was to evaluate the long-term safety and tolerability of 7-day BTDS in a 28-week open-label extension phase in subjects with chronic nonmalignant pain syndromes whose pain had been previously controlled by oral opioid combination therapy.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) as a Measure of Safety.","timeFrame":"28 weeks","effectByArm":[{"arm":"Total Extension Phase","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":189},"commonTop":["Erythema at site","Pruritus at site","Rash at site","Nausea","Somnolence"]}}